Evidence map›Paper›PMID 31333650›Full record

ArticleFrontiers in immunology2019

Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children.

Julia Roider, J Zachary Porterfield, Paul Ogongo, Maximilian Muenchhoff, Emily Adland, Andreas Groll, Lynn Morris, Penny L Moore, Thumbi Ndung'u, Henrik Kløverpris and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 6 countries.

Julia RoiderAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
J Zachary PorterfieldAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Paul OgongoAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Maximilian MuenchhoffDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Emily AdlandDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Andreas GrollFaculty of Statistics, TU Dortmund University, Dortmund, Germany.
Lynn MorrisCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Penny L MooreCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Thumbi Ndung'uAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Henrik KløverprisAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Philip J R GoulderDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Alasdair LeslieAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Africa Health Research Institute · ZAUniversity of Oxford · GBUniversity of the Witwatersrand · ZANational Museums of Kenya · KERagon Institute of MGH, MIT and Harvard · USTU Dortmund University · DEUniversity College London · GBUniversity of KwaZulu-Natal · ZAYale University · US

Funding

TRAINING IN THE PATHOGENESIS OF INFECTIOUS DISEASEST32AI007517 · NIAID · YALE UNIVERSITY · PI Jaimie Meyer, Albert C Shaw · 1997 to 2026
$6.1M
Maximising Cure Potential in Paediatric HIV InfectionR01AI133673 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2017 to 2021
$1.4M
NIAID NIH HHS R01 AI133673NIAID NIH HHS T32 AI007517Wellcome Trust
6 · The paper itself

Abstract

Children may be the optimal target for HIV vaccine development as they generate substantially more frequent and more potent broadly HIV neutralizing antibodies (bnAbs) than adults. Development of a biomarker that correlates with neutralization breadth in this group could function as a powerful tool to facilitate the development of an HIV vaccine. Previously, we observed that this preferential ability in HIV-infected children over adults to generate bnAbs is associated with an enrichment of circulating follicular helper T-cells (T

Indexed as

ActivinsAdolescentBiomarkersBroadly Neutralizing AntibodiesChemokine CXCL13ChildCohort StudiesDisease ProgressionGerminal CenterHIV-1HIV AntibodiesHIV InfectionsHumansInterleukin-5Neutralization TestsT-Lymphocytes, Helper-Induceractivin AActivinsBiomarkersBroadly Neutralizing AntibodiesChemokine CXCL13CXCL13 protein, humanHIV AntibodiesIL5 protein, humanInterleukin-5Activin Abroadly neutralizing antibodies (bnAbs)CXCL13HIV neutralization breadthIL-5pediatric HIVplasma markersT-follicular helper cells (Tfh)

Identifiers

PMID31333650
PMCPMC6615198
OpenAlexW2953705395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.